Rich B. shares his experience with his immunotherapy treatment (nivolumab or commercial name Opdivo) for his stage 3B melanoma, as well as side effects. Thank you, Rich, for sharing your story. In this Series: Our 5-part series with Rich covers his entire Melanoma cancer experience: 1) My Melanoma First Symptoms & Tests → https://youtu.be/dmuBj0lxaIE 2) The Surgery & Melanoma Staging → https://youtu.be/LdXVbSsoNIc 3) Treatment Decisions & Importance of Self-Advocacy → https://youtu.be/2cKQLiQ7Vy

Current standard immunotherapy with medications such as keytruda, opdivo or yervoy results vary depending on many factors with a 24 month survival rate of 53% in melanoma, a better responding cancer, with occasional cures. These therapies are expensive, have side effects and still are lacking in results. We now have made a quantum leap in cancer treatment by adding ablation with vaccine adjuvants, completely blowing away the results of standard immunotherapy. https://williamscancerinstitute.com

The FDA recently approved the immunotherapy combination Nivolumab plus Ipilimumab for patients with metastatic melanoma. Hear from Karen, a participant in the clinical trial, as she describes her journey. | Memorial Sloan Kettering Cancer Center